US FDA: No Timeframe On Combo Products Council Response To Industry Feedback
Executive Summary
Industry stakeholders are still confused about the scope of the recently formed Combination Products Policy Council. In the meantime, the council says it doesn't have a specific timeframe by which it will address the issues industry has identified as priority topics.
You may also be interested in...
US FDA Works To Finalize 3D Printing Guidance; Industry Asks For More
A top FDA device official says the agency is hoping to finalize an additive manufacturing guidance this year. Industry is particularly interested in seeing the leap-frog guidance made final, but would also like to see more clarification and a separate guidance to address the topic of patient-specific manufacturing.
Companies Want New US FDA Council To Help Resolve Inter-Agency Combo Product Disputes
A range of topics were raised in feedback provided by industry groups to FDA about what the priorities should be for the agency's new Combination Products Policy Council, but addressing inter-center disagreements was a repeat concern. Also raised: misaligned communication policies; pediatric combo-product reviews; and implementation of the 21st Century Cures Act.
PDUFA First: Fees To Support US FDA Device Center Staff
To enhance combination product reviews, drug-fee revenue will pay for related positions in the agency's Center for Devices and Radiological Health.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: